From disease eradication efforts to advances in vaccination and maternal health, this archive tracks real progress in public health. Stories here focus on what’s working — policies, interventions, and research that are improving and extending lives around the world.
The age-adjusted prevalence of dementia declined from 12.2 percent of people over age 65 in 2000 to 8.5 percent of people over age 65 in 2016—a nearly one-third drop from the 2000 level, according to a new RAND Corporation study.
Pancreatic cancer is one of the hardest diseases medicine has ever faced, and a new implant from Duke University is producing results that researchers say have no match in the existing scientific record. The device injects a radioactive gel directly into tumors, trapping iodine-131 so it radiates from the inside out before safely dissolving into harmless amino acids. Combined with chemotherapy, it eliminated tumors in the majority of mouse models tested. Human trials remain ahead, but for a disease where survival gains have been painfully slow, this early signal is genuinely remarkable.
Psilocybin therapy is making history: Compass Pathways will launch the world’s first Phase 3 trial for treatment-resistant depression by the end of 2022, enrolling nearly 1,000 participants across two pivotal studies. This is the threshold every promising drug must cross to become an approved medicine, and no psychedelic compound has crossed it before. For the roughly 100 million people worldwide whose depression doesn’t respond to standard treatments, the stakes are real — current options are few, often invasive, and inconsistently helpful. A single guided dose, if the evidence holds, could reshape what care looks like. Beyond depression, this moment signals that a long-stigmatized class of medicines is finally being tested with the rigor patients deserve.
The money will be used to help implement the Global Polio Eradication Initiative’s strategy through 2026 and will be focused particularly on Pakistan and Afghanistan.
Zimbabwe just became the first country in Africa to approve cabotegravir, a long-acting HIV prevention injection given once every two months — joining only Australia and the United States. For young women and girls especially, that change is huge: a single shot replaces the daily pill regimen that stigma, privacy concerns, and patchy healthcare often make hard to sustain. It builds on a remarkable turnaround, with AIDS-related deaths in Zimbabwe falling from roughly 130,000 in 2002 to about 20,000 in 2021. As advocate Nyasha Sithole put it, ending the epidemic requires a real “basket of tools.” Zimbabwe’s quick action sends a powerful signal that African regulators don’t have to wait in line for life-saving HIV breakthroughs.
Spina bifida causes nerve damage that accumulates in the womb, and until now, medicine could only respond after that damage was done. A clinical trial at UC Davis Health is changing that window, applying a stem cell patch directly to a fetus’s spine during pregnancy to support repair before birth. The first baby treated was expected to arrive with leg paralysis — instead, she was kicking and wiggling her toes. If results hold across all 35 enrolled patients, this could establish a genuinely new standard of care for a condition that currently offers families very little hope.
The coal-fired Loy Yang A power station near Melbourne – responsible for more than three percent of the country’s emissions – will shut down in 2035, a decade earlier than planned.
A French research company interviewed more than 4,000 adults across France, Germany, Italy, and Spain. More than 50% reported having reduced their meat consumption in the last five years largely for environmental, animal welfare, and personal health reasons.
CERVAVAC, India’s first homegrown cervical cancer vaccine, is priced at just $2.50 to $5.00 per dose — a fraction of what HPV vaccines have cost in wealthy countries for nearly two decades. Developed by the Serum Institute of India, it protects against the HPV strains responsible for the majority of cervical cancers worldwide, and the company aims to produce around 200 million doses in its first two years. Cervical cancer is almost entirely preventable, yet it still kills hundreds of thousands of women each year, mostly in lower-income countries where vaccines have been priced out of reach. An affordable, locally made option doesn’t just change the math for India — it points toward a future where health tools belong to the people who need them most.
Lupus remission in all five patients — that’s the striking result from a small German trial using CAR T-cell therapy, a treatment originally developed for blood cancers. Doctors collected each patient’s own T-cells, reprogrammed them to clear out the malfunctioning B cells driving the disease, and reinfused them. Months later, the patients’ immune systems had essentially rebooted: new B cells grew back, but they no longer attacked the body. None have needed lupus medication since. The lead researcher believes the same approach could help people with rheumatoid arthritis, multiple sclerosis, and other autoimmune conditions — opening a hopeful new chapter for millions worldwide who have long managed their illness without ever truly being free of it.
